Evidence map›Paper›PMID 42787936›Full record

ArticleThe journal of liquid biopsy2026

Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial.

Davide Ciardiello, Giulia Martini, Luca Boscolo Bielo, Gloria Pellizzari, Filippo Pietrantonio, Paola Andena, Silvia Marchesi, Salvatore Pisconti, Claudia Nisi, Giampaolo Tortora and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Davide CiardielloDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milano, Italy.
Giulia MartiniDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Luca Boscolo BieloDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milano, Italy.
Gloria PellizzariDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milano, Italy.
Filippo PietrantonioDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Paola AndenaDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Silvia MarchesiDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Salvatore PiscontiMedical Oncology Unit, San Giuseppe Moscati Hospital, Statte, Italy.
Claudia NisiMedical Oncology Unit, San Giuseppe Moscati Hospital, Statte, Italy.
Giampaolo TortoraMedical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
Lisa SalvatoreMedical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
Andrea Sartore-BianchiDepartment of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
Salvatore SienaDepartment of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
Federica PapaccioDepartment of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, 84081, Italy.
Marco MessinaMedical Oncology Unit, A.R.N.A.S. Ospedali Civico di Cristina Benfratelli (PA), Palermo, 90127, Italy.
Elena OngaroUnit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Alberto ZaniboniMedical Oncology Unit, Fondazione Poliambulanza, Brescia, Italy.
Carmine PintoMedical Oncology Unit, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Florence, Italy.
Antonio AvalloneExperimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
Nicola NormannoCenter for Advanced Molecular Diagnostics in Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
Giuseppe SantabarbaraMedical Oncology Unit, San Giuseppe Moscati Hospital, Avellino, Italy.
Maria Giulia ZampinoDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milano, Italy.
Alessandra Pia D'AgataDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milano, Italy.
Rossana BerardiDepartment of Medical Oncology, Marche Polytechnic University, Ancona, Italy.
Alessio CogoniMedical Oncology Unit, University Hospital (AOU) of Sassari, Sassari, Italy.
Claudio LotesoriereMedical Oncology Unit, National Institute of Gastroenterology, IRCCS de Bellis Research Hospital, Castellana Grotte, Italy.
Tiziana Pia LatianoMedical Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Carminia Maria Della CorteDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Nicola FazioDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milano, Italy.
Giuseppe CuriglianoDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milano, Italy.
Roberto BordonaroMedical Oncology Unit, Azienda Ospedaliera ARNAS Garibaldi, Catania, Italy.
Teresa TroianiDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Ferdinando De VitaDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Erika MartinelliDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Fortunato CiardielloDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Stefania NapolitanoDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetuximab ± avelumab in patients with circulating tumor DNA (ctDNA) (assessed with the FoundationOne Liquid assay)

Indexed as

Anti-EGFR rechallengeCetuximabctDNA tumor fractionLiquid biopsyMolecular hyperselection

Identifiers

PMID42787936
PMCPMC13602321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.